Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology

Overview Zen Rating Price Value Growth Financials

Momentum Sentiment Forecast Dividends Due Diligence

Biotech is Zen Rated F and is the 140th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	ROE	ROA	ROCE	ROIC	D/E	Current Ratio	Gross Margin	Profit Margin	Operating Margin
SCNI	SCINAI IMMUNOTHERAPEUTICS LTD	$0.00	-253.10%	-33.30%	-52.58%	-29.10%	0.35	1.32	-88.10%	-728.90%	-930.24%
SLGL	SOL-GEL TECHNOLOGIES LTD	$35.10M	-32.30%	-26.30%	-34.62%	-53.40%	0.24	5.92	100.00%	-91.70%	-91.70%
ARTL	ARTELO BIOSCIENCES INC	$6.49M	-226.30%	-164.10%	-1,366.39%	-2,746.30%	4.39	0.49	N/A	N/A	N/A
ARMP	ARMATA PHARMACEUTICALS INC	$88.67M	N/A	-0.40%	-51.94%	11.30%	-2.62	0.12	100.00%	-10.10%	287.48%
CASI	CASI PHARMACEUTICALS INC	$20.14M	-972.60%	-77.30%	-555.33%	-134.40%	-6.06	0.81	41.30%	-129.00%	-125.84%
CMND	CLEARMIND MEDICINE INC	$5.13M	-164.80%	-71.10%	-201.37%	143.10%	1.25	1.75	N/A	N/A	N/A
ORMP	ORAMED PHARMACEUTICALS INC	$87.83M	-18.20%	-17.30%	-25.26%	-38.00%	0.05	23.94	0.60%	-1,411.90%	-1,794.30%
LVTX	LAVA THERAPEUTICS NV	$39.98M	-86.70%	-34.20%	-43.78%	-70.40%	1.76	6.73	100.00%	-561.90%	-533.29%
APRE	APREA THERAPEUTICS INC	$9.40M	-68.40%	-55.70%	-90.69%	635.50%	0.30	5.90	100.00%	-1,096.30%	-1,190.51%
AZTR	AZITRA INC	$2.93M	-183.10%	-135.20%	-196.25%	-536.30%	0.34	3.02	100.00%	-121,372.80%	-121,085.24%
KTTA	PASITHEA THERAPEUTICS CORP	$5.40M	-88.10%	-81.20%	-104.16%	3,238.60%	0.13	3.84	N/A	N/A	N/A
APM	APTORUM GROUP LTD	$8.69M	-18.60%	-23.20%	-34.95%	-24.30%	0.21	0.22	N/A	N/A	N/A
ANTX	AN2 THERAPEUTICS INC	$31.99M	-53.20%	-47.80%	-61.85%	-75.70%	0.11	8.68	N/A	N/A	N/A
CELZ	CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC	$7.19M	-85.30%	-81.50%	-75.55%	3,422.40%	0.04	27.39	60.00%	-43,500.20%	-43,500.24%
MOLN	MOLECULAR PARTNERS AG	$136.39M	-42.20%	-38.10%	-44.14%	-73.80%	0.10	15.28	100.00%	-2,665.30%	-2,613.31%
BCDA	BIOCARDIA INC	$11.08M	-30,792.70%	-223.10%	785.67%	1,080.60%	-2.43	0.36	100.00%	-279,700.00%	-279,700.00%
BCAB	BIOATLA INC	$17.44M	-357.90%	-111.70%	-277.67%	601.20%	69.00	2.35	100.00%	-562.50%	-562.51%
SER	SERINA THERAPEUTICS INC	$55.22M	N/A	-11.90%	-15.16%	-43.80%	3.04	2.45	100.00%	-1,841.20%	-1,301.96%
APLT	APPLIED THERAPEUTICS INC	$63.71M	-101.20%	-46.10%	-111.73%	105.40%	0.55	3.00	100.00%	-16,357.50%	-16,357.52%
AIM	AIM IMMUNOTECH INC	$2.23M	-1,586.20%	-137.80%	414.07%	-4,914.30%	-2.62	0.27	77.40%	-10,416.40%	-9,980.14%
MNOV	MEDICINOVA INC	$64.99M	-20.80%	-19.70%	-22.18%	-288.40%	0.05	17.66	N/A	N/A	N/A
QNRX	QUOIN PHARMACEUTICALS LTD	$6.90M	-149.00%	-77.20%	-128.99%	-187.80%	1.19	2.57	N/A	N/A	N/A
TCRT	ALAUNOS THERAPEUTICS INC	$4.67M	-169.30%	-124.30%	-384.78%	-401.10%	1.00	1.01	100.00%	-50,887.50%	-50,887.50%
ADAG	ADAGENE INC	$93.75M	-55.20%	-32.60%	-63.80%	343.60%	0.77	2.30	100.00%	-32,386.40%	-31,578.03%
PPBT	PURPLE BIOTECH LTD	$111.70M	12.70%	10.90%	13.50%	-167.70%	0.09	2.73	N/A	N/A	N/A
SLRX	SALARIUS PHARMACEUTICALS INC	$1.27M	-324.10%	-174.40%	-9,003.36%	684.80%	36.81	1.01	N/A	N/A	N/A
ADIL	ADIAL PHARMACEUTICALS INC	$3.44M	-218.90%	-177.60%	-420.83%	-2,065.90%	0.62	1.99	N/A	N/A	N/A
SNGX	SOLIGENIX INC	$9.56M	-223.90%	-103.50%	-279.76%	385.20%	1.14	1.85	0.00%	-409,394.20%	-431,521.39%
SYBX	SYNLOGIC INC	$18.01M	10.90%	7.50%	11.48%	-29.00%	0.37	3.68	N/A	N/A	N/A
SRZN	SURROZEN INC	$85.63M	N/A	-127.50%	-78.38%	-843.30%	19.24	10.02	100.00%	-766.80%	-766.81%
XTLB	XTL BIOPHARMACEUTICALS LTD	$12.34M	-26.80%	-18.70%	-18.24%	911.00%	0.57	0.61	0.70%	-227.70%	-256.54%
LSB	LAKESHORE BIOPHARMA CO LTD	$156.46M	-41.10%	-15.70%	-31.61%	-21.60%	1.38	1.17	80.60%	-35.50%	-33.03%
VRNA	VERONA PHARMA PLC	$8.95B	-89.80%	-36.10%	-26.10%	-48.40%	1.32	8.86	94.90%	-138.30%	-103.34%
NXTC	NEXTCURE INC	$11.59M	-70.20%	-58.10%	-80.66%	-86.50%	0.20	10.26	N/A	N/A	N/A
MEIP	MEI PHARMA INC	$34.31M	-127.20%	-110.80%	-162.03%	-283.50%	0.06	16.78	N/A	N/A	N/A
LIXT	LIXTE BIOTECHNOLOGY HOLDINGS INC	$10.66M	-237.50%	-189.30%	-285.68%	1,253.10%	0.31	4.26	N/A	N/A	N/A
KPRX	KIORA PHARMACEUTICALS INC	$7.91M	-42.80%	-32.20%	-34.24%	-46.30%	0.44	5.14	100.00%	-60,257.30%	-49,209.99%
VTVT	VTV THERAPEUTICS INC	$47.76M	-144.90%	-46.70%	-67.44%	436.00%	2.92	7.40	100.00%	-109,935.30%	-109,935.29%
VERU	VERU INC	$71.09M	-123.60%	-73.60%	-130.98%	-284.10%	0.55	3.80	37.90%	-342.60%	-333.95%
MLEC	MOOLEC SCIENCE SA	$12.80M	-150.90%	-26.60%	-25.84%	-22.10%	10.22	1.48	-8.20%	-105.70%	-82.22%
CSCI	COSCIENS BIOPHARMA INC	$12.27M	-101.00%	-43.90%	-70.30%	-129.20%	2.07	2.88	47.30%	-194.50%	-187.49%
INKT	MINK THERAPEUTICS INC	$60.42M	N/A	-140.70%	124.01%	292.10%	-1.20	0.30	N/A	N/A	N/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Aug 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Ptc Therapeutics (NASDAQ:PTCT)

Ptc Therapeutics (NASDAQ:PTCT) is the #1 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.

PTCT passed 11 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 53.94% over the past year, overperforming other biotech stocks by 122 percentage points.

Ptc Therapeutics has an average 1 year price target of $69.62, an upside of 33.59% from Ptc Therapeutics's current stock price of $52.11.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 53.85% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.

2. Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) is the #2 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 49, which is 26 points higher than the biotech industry average of 23.

PBYI passed 16 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock lose -13.25% over the past year, overperforming other biotech stocks by 54 percentage points.

Puma Biotechnology has an average 1 year price target of $7.00, an upside of 125.08% from Puma Biotechnology's current stock price of $3.11.

Puma Biotechnology stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) is the #3 top biotech stock out of 642 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 35, which is 12 points higher than the biotech industry average of 23.

RIGL passed 11 out of 33 due diligence checks and has average fundamentals. Rigel Pharmaceuticals has seen its stock return 99.05% over the past year, overperforming other biotech stocks by 167 percentage points.

Rigel Pharmaceuticals has an average 1 year price target of $39.75, an upside of 88.75% from Rigel Pharmaceuticals's current stock price of $21.06.

Rigel Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Rigel Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 7.03%, which is 5 percentage points higher than the biotech industry average of 1.88%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 3.42%, which is 2 percentage points higher than the biotech industry average of 1.88%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.77%, which is the same as the biotech industry average of 1.88%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 34.4% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 0.35% in the last day, and down -1.82% over the last week. Soligenix was the among the top gainers in the biotechnology industry, gaining 134.4% yesterday.

Soligenix shares are trading higher after the company announced positive Phase 2a proof-of-concept results for SGX945 in Behçet's Disease, demonstrating biological efficacy.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -13.25% in the past year. It has overperformed other stocks in the biotech industry by 54 percentage points.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 3.9% in the past year. It has overperformed other stocks in the biotech industry by 72 percentage points.

3. United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -12.32% in the past year. It has overperformed other stocks in the biotech industry by 55 percentage points.

Are biotech stocks a good buy now?

53.02% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 100.43% over the next year.

2.11% of biotech stocks have a Zen Rating of A (Strong Buy), 4.21% of biotech stocks are rated B (Buy), 37.26% are rated C (Hold), 36.42% are rated D (Sell), and 20% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -201.28x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Biotech Stocks FAQ

1. Ptc Therapeutics (NASDAQ:PTCT)

2. Puma Biotechnology (NASDAQ:PBYI)

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

1. Dominari Holdings (NASDAQ:DOMH)

2. Novo Nordisk (Ozempic) (NYSE:NVO)

3. Royalty Pharma (NASDAQ:RPRX)

1. Puma Biotechnology (NASDAQ:PBYI)

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

3. United Therapeutics (NASDAQ:UTHR)

Company

Stock Tools

Stock Ideas

Sectors & IndustriesHealthcareBiotechnologyBest Biotech Stocks to Buy Now (2025)Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Biotech Stocks FAQ

1. Ptc Therapeutics (NASDAQ:PTCT)

2. Puma Biotechnology (NASDAQ:PBYI)

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

1. Dominari Holdings (NASDAQ:DOMH)

2. Novo Nordisk (Ozempic) (NYSE:NVO)

3. Royalty Pharma (NASDAQ:RPRX)

1. Puma Biotechnology (NASDAQ:PBYI)

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

3. United Therapeutics (NASDAQ:UTHR)

Company

Stock Tools

Stock Ideas

Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.